| 1. |
- Bravo, L, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 2. |
- Tabiri, S, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Trempenau, ML, et al.
(författare)
-
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes
- 2023
-
Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 37:3, s. 593-605
-
Tidskriftsartikel (refereegranskat)abstract
- Epigenetic regulators are frequently mutated in hematological malignancies including acute myeloid leukemia (AML). Thus, the identification and characterization of novel epigenetic drivers affecting AML biology holds potential to improve our basic understanding of AML and to uncover novel options for therapeutic intervention. To identify novel tumor suppressive epigenetic regulators in AML, we performed an in vivo short hairpin RNA (shRNA) screen in the context of CEBPA mutant AML. This identified the Histone 3 Lysine 4 (H3K4) demethylase KDM5C as a tumor suppressor, and we show that reduced Kdm5c/KDM5C expression results in accelerated growth both in human and murine AML cell lines, as well as in vivo in Cebpa mutant and inv(16) AML mouse models. Mechanistically, we show that KDM5C act as a transcriptional repressor through its demethylase activity at promoters. Specifically, KDM5C knockdown results in globally increased H3K4me3 levels associated with up-regulation of bivalently marked immature genes. This is accompanied by a de-differentiation phenotype that could be reversed by modulating levels of several direct and indirect downstream mediators. Finally, the association of KDM5C levels with long-term disease-free survival of female AML patients emphasizes the clinical relevance of our findings and identifies KDM5C as a novel female-biased tumor suppressor in AML.
|
|
| 8. |
|
|
| 9. |
- De Angelis, A., et al.
(författare)
-
All-Sky-ASTROGAM : a MeV Companion for Multimessenger Astrophysics
- 2021
-
Ingår i: Proceedings of Science. - : Sissa Medialab Srl.
-
Konferensbidrag (refereegranskat)abstract
- In the era of multi-messenger astronomy it is of paramount importance to have in space a gamma-ray monitor capable of detecting energetic transients in the energy range from 0.1 MeV to a few hundred MeV, with good imaging capabilities. The All-Sky-ASTROGAM mission proposal aims to place into an L2 orbit a gamma-ray instrument (∼ 100 kg) dedicated to fast detection, localization, and gamma-ray spectroscopy of flaring and merging activity of compact objects in the Universe, with unprecedented sensitivity and polarimetric capability in the MeV range. The instrument is based on the ASTROGAM concept, which combines three detection systems of space-proven technology: a silicon tracker in which the cosmic gamma rays undergo Compton scattering or a pair conversion, a scintillation calorimeter to absorb and measure the energy of the secondary particles, and an anticoincidence system to veto the prompt reaction background induced by charged particles. The gamma-ray imager and the platform will be connected through a boom and will have almost no occultation, making possible a continuous monitoring of every single gamma-ray source in the sky during the entire mission lifetime.
|
|
| 10. |
- Byskata, K, et al.
(författare)
-
Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited
- 2023
-
Ingår i: Cancers. - : MDPI AG. - 2072-6694. ; 15:1
-
Tidskriftsartikel (refereegranskat)abstract
- Human papillomavirus positive (HPV+) tonsillar and base of tongue cancer (TSCC/BOTSCC) is rising in incidence, but chemoradiotherapy is not curative for all. Therefore, targeted therapy with PI3K (BYL719), PARP (BMN-673), and WEE1 (MK-1775) inhibitors alone or combined was pursued with or without 10 Gy and their effects were analyzed by viability, proliferation, and cytotoxicity assays on the TSCC/BOTSCC cell lines HPV+ UPCI-SCC-154 and HPV− UT-SCC-60A. Effective single drug/10 Gy combinations were validated on additional TSCC lines. Finally, APR-246 was assessed on several TSCC/BOTSCC cell lines. BYL719, BMN-673, and MK-1775 treatments induced dose dependent responses in HPV+ UPCI-SCC-154 and HPV− UT-SCC-60A and when combined with 10 Gy, synergistic effects were disclosed, as was also the case upon validation. Using BYL719/BMN-673, BYL719/MK-1775, or BMN-673/MK-1775 combinations on HPV+ UPCI-SCC-154 and HPV− UT-SCC-60A also induced synergy compared to single drug administrations, but adding 10 Gy to these synergistic drug combinations had no further major effects. Low APR-246 concentrations had limited usefulness. To conclude, synergistic effects were disclosed when complementing single BYL719 BMN-673 and MK-1775 administrations with 10 Gy or when combining the inhibitors, while adding 10 Gy to the latter did not further enhance their already additive/synergistic effects. APR-246 was suboptimal in the present context.
|
|
